We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+46.36%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$7.86B
AUM Growth
+$1.46B
Cap. Flow
+$137M
Cap. Flow %
1.74%
Top 10 Hldgs %
51.1%
Holding
83
New
21
Increased
18
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$142M
2
DYN icon
Dyne Therapeutics
DYN
+$112M
3
EVH icon
Evolent Health
EVH
+$102M
4
LENZ
LENZ Therapeutics
LENZ
+$86.9M
5
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$71.7M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$704M
2
CBAY
Cymabay Therapeutics
CBAY
+$164M
3
ICVX
Icosavax, Inc. Common Stock
ICVX
+$94M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$93.6M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$76.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Miscellaneous 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX
26
DELISTED
Inhibrx, Inc. Common Stock
INBX
$91.9M 1.17%
2,629,837
-2,094,370
-44% -$76.4M
RNAM
27
DELISTED
Avidity Biosciences
RNAM
$83.8M 1.07%
3,282,180
+827,647
+34% +$13M
AXSM icon
28
Axsome Therapeutics
AXSM
$10.7B
$79.8M 1.02%
1,000,000
– –
LBPH
29
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$71M 0.9%
+3,289,119
New +$71.7M
DNTH icon
30
Dianthus Therapeutics
DNTH
$5.86B
$70M 0.89%
+2,333,000
New +$50.7M
GHRS icon
31
GH Research
GHRS
$1.89B
$66.6M 0.85%
6,251,714
+664,381
+12% +$5.28M
GPCR icon
32
Structure Therapeutics
GPCR
$2.78B
$64.7M 0.82%
1,510,362
+1,023,530
+210% +$43.2M
MLYS icon
33
Mineralys Therapeutics
MLYS
$2.56B
$62.6M 0.8%
4,850,984
+1,672,508
+53% +$20.7M
ATXS
34
DELISTED
Astria Therapeutics
ATXS
$62.1M 0.79%
+4,413,150
New +$55M
CGON icon
35
CG Oncology
CGON
$6.43B
$61.3M 0.78%
+1,397,433
New +$57.1M
ABOS icon
36
Acumen Pharmaceuticals
ABOS
$209M
$60.5M 0.77%
14,932,063
– –
ITOS
37
DELISTED
iTeos Therapeutics
ITOS
$60.3M 0.77%
4,417,259
– –
SLDB icon
38
Solid Biosciences
SLDB
$897M
$57.7M 0.73%
4,330,446
+904,160
+26% +$8.46M
MDGL icon
39
Madrigal Pharmaceuticals
MDGL
$12.1B
$54.6M 0.69%
204,500
– –
VOR icon
40
Vor Biopharma
VOR
$1.32B
$53.9M 0.69%
1,137,444
– –
PRAX icon
41
Praxis Precision Medicines
PRAX
$8.74B
$50.5M 0.64%
+828,380
New +$37.2M
URGN icon
42
UroGen Pharma
URGN
$2.04B
$46.3M 0.59%
3,083,430
– –
LRMR icon
43
Larimar Therapeutics
LRMR
$406M
$45.9M 0.58%
+6,045,351
New +$47.1M
CTKB icon
44
Cytek Biosciences
CTKB
$636M
$45.7M 0.58%
6,809,404
– –
CCCC icon
45
C4 Therapeutics
CCCC
$422M
$39.9M 0.51%
4,878,000
– –
HOWL icon
46
Werewolf Therapeutics
HOWL
$47.6M
$39.8M 0.51%
6,144,881
– –
ELVN icon
47
Enliven Therapeutics
ELVN
$3.91B
$37.3M 0.48%
2,122,465
– –
CLYM
48
Climb Bio
CLYM
$799M
$36M 0.46%
13,150,849
– –
ACRV icon
49
Acrivon Therapeutics
ACRV
$78.4M
$34.4M 0.44%
4,810,508
– –
TSHA icon
50
Taysha Gene Therapies
TSHA
$1.65B
$31.2M 0.4%
10,872,503
-7,600,000
-41% -$15.8M
1
2
3 4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, RA Capital Management held 83 positions worth $7.86B, up 23% from $6.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management's Q1 2024 filing shows 21 new, 18 increased, 5 reduced and 7 closed positions. Its largest new stake was Edgewise Therapeutics: 8,909,091 shares worth $163M. The largest sale was Immunogen Inc, an estimated $704M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • RA Capital Management's largest Q1 2024 buy was Edgewise Therapeutics: 8,909,091 shares worth $163M.
  • RA Capital Management added most to Evolent Health in Q1 2024, an estimated $102M increase.
  • RA Capital Management's biggest Q1 2024 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $76.4M.
  • RA Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $704M.
  • RA Capital Management's ten largest holdings make up 51% of its $7.86B portfolio in Q1 2024.
  • RA Capital Management opened 21 new positions and closed 7 in Q1 2024.
  • RA Capital Management's portfolio value rose 23% quarter-over-quarter to $7.86B.

Based on RA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.